Select Page

MDSTreatment paradigms for MDS are changing.

Our most recent syndicated survey will tell you how and why.

Patients with Myelodysplastic syndrome (MDS), particularly high-risk patients (based on the revised International Prognostic Scoring System IPSS-R), face very poor outcomes, where median survival has been reported as being just 9 months. In addition to poor outcomes, many MDS patients will see their disease transform into AML, where the risk of AML increases with a worsening prognostic risk score. In recent years, a wave of new product developments and treatment options for MDS patients of all risk groups were introduced which are expected to change the treatment paradigm and outcomes for patients.  

Capitalizing on our unique expertise as pioneers of patient chart-based research, we offer subscriptions to our real-world data providing insights and the latest understanding of changing paradigms in the treatment of MDS across all types. Importantly, as the classification system changes, MDSsyndiTrack also captures the physician perceptual classification vs the real-world classification (% myeloblasts) of patients with MDS vs AML-MRC.

Example of a recent wave:

  • data collected in Q4 22 in Germany, France, Italy,  Spain , USA, Japan, and China
  • Over 500 Onco-hematologists
  • over 3,000 real-world MDS patient charts
  • Back data available for the UK, Germany, France, Italy, Spain,
    Canada, Austria, Belgium, Netherlands, Sweden, Brazil


More information about our MDS syndicated study?

  • Objectives 
  • Benefits
  • Samples
  • Scope
  • Types of data collected
  • Dates of research waves

Fill in the form to see a 2-page helicopter view of MDSsyndiTrack with more details on the data collection and a few examples of outputs.

More information about the MDS syndicated study? Fill out the form below and we will be in touch shortly.

Go further with the data and discover an example of a Digital & Interactive Dashboard (DID) created by APLUSA

We take here the example of a patient share tracker in Cancer X syndiTrackTM.
The dashboard is built around 6 variables: the country, the treatment start date, the treatment line, the product or regimen, risk factors and market share.

In total, there are many advantages of using this DID:
- your data is available online and can be easily shared within your organization,
- you can create your own views instead of manipulating a large number of powerpoint slides,
- you always have the latest data available, no update problems,
- the data is available on your dashboard much earlier in the data collection,
- the report will be more focused on key insights and storytelling than on data production.

👇 Test our live demo here! 👇